[New Year's Message] Kim Kyung-ah, President of Sambaepis, "Biosimilars including 'Pizzchiba' to Launch in the US This Year"

"Prepare for the Second Leap"

Kim Kyung-ah, President of Samsung Bioepis, stated in her New Year's address on the 2nd, "In 2025, the launch of biosimilars such as 'Fiztiva' in the United States is planned," adding, "The passion of all employees is necessary to achieve this goal."

Kim Kyung-ah, President of Samsung Bioepis. Samsung Bioepis

Samsung Bioepis is preparing for the U.S. launch of Fiztiva this year, as well as global approvals for the Prolia biosimilar 'Obodens' and the Xgeva biosimilar 'Xbrick.'

Fiztiva is a biosimilar of Stelara, an autoimmune disease treatment developed by Janssen. Prolia, developed by Amgen, is used for treating osteoporosis and bone loss in cancer patients, and with the same active ingredient, it is also approved under the product name Xgeva for preventing bone metastasis complications in cancer patients.

President Kim emphasized that for the launch and approval of these products, "interdepartmental cooperation, passion, and responsibility for work are essential," and added, "Developing competitive products through work efficiency and continuous challenges for sustainable growth are indispensable."

She continued, "This year, we will create an opportunity to become a global bio company and prepare for a second leap forward."

This content was produced with the assistance of AI translation services.